I am a healthcare professional
If you are a healthcare professional looking to find out more about heavy menstrual bleeding and contraception, please click below.
If you are not a healthcare professional and you want to learn about contraception please click below.
If you are not a healthcare professional and you want to learn about heavy menstural bleedingplease click below.

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Bayer logo

Welcome to Women's Health Matters, an online resource to support healthcare professionals involved in the area of Women's Health.

Clinical guidelines

Access the latest clinical guidelines in women’s health

Keep up-to-date with the latest evidence-based recommendations in women’s health, including the management of menorrhagia and assessment for contraceptive options.

To view everything NICE says in an interactive flowchart, visit Treatment pathways

Visit page


NICE Guideline NG88. Heavy menstrual bleeding: assessment and management (March 2018 - November 2018 update).


This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

NICE Guideline NG88

When should I refer a woman with menorrhagia?


NICE Clinical Knowledge Summary: menorrhagia (updated December 2018) covers the recommended management of heavy menstrual bleeding, including criteria for referral to secondary care.

when should I refer a woman with menorrhagia

Five top tips for managing heavy menstrual bleeding


Resource from Primary Care Women’s Health Forum Her Life Her Health (Issue 1) setting out five top tips for managing heavy menstrual bleeding.

NICE Guideline NG88


NICE Guideline CG30: Long-acting reversible contraception


This guideline covers long-acting reversible contraception. It aims to increase the use of long-acting reversible contraception by improving the information given to women about their contraceptive choices.

Long-acting reversible contraception

NICE Clinical Knowledge Summary: Contraception – assessment (updated September 2019).


Five scenarios covering the different methods of contraception and the general principles of how to help a woman choose the one that is suitable for her and her partner.

NICE Clinical Knowledge Summary

NICE: Clinical Knowledge Summary: Contraception – IUS/IUD (updated May 2019).


Two scenarios covering when to start using IUS/IUD; managing common and uncommon problems; the advantages, disadvantages, risks, and efficacy; and the subsequent monitoring and follow-up required.

NICE Clinical Knowledge Summary

FSRH: The faculty of sexual and reproductive healthcare of the Royal College of Obstetricians & Gynaecologists

The FRSH are the largest UK professional membership organisation working at the heart of sexual and reproductive health, supporting healthcare professionals to deliver high-quality care.

They have a specialist committee of sexual and reproductive health (SRH) doctors and nurses that produce training programmes, conferences and events and clinical guidance and other FSRH learning resources.


FSRH Clinical Guideline: Intrauterine contraception (updated September 2019).


This guidance provides evidence-based recommendations and good practice points for health professionals on the use of intrauterine contraception (IUC) currently available in the UK. Please note that the FSRH includes some off-label uses of medications in their guidelines. Please refer to the current SmPC before prescribing.


The FSRH has announced a new diploma will open for applications in Spring 2020.

Find out more

Public Health England: Protecting and improving the nation's health and wellbeing, while reducing health inequalities.

Public Health England are an executive agency of the Department of Health and Social Care, and a distinct organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific expertise and support.


Public Health England (2018): Reproductive health is a public health issue


One of 3 documents that aims to define the scope and vision for reproductive health. Expressed as a set of shared values on which to base future models of care that works for the user across the whole reproductive life-course.


Public Health England (2018), What do women say?


Presenting the findings from a survey of more than 7,500 women and focus group discussions to understand how women experience reproductive health issues and some of the choices they make.


Public Health England (2017): Sexual health, reproductive health and HIV: commissioning review


This report identifies the commissioning challenges faced by commissioners and providers, and makes recommendations designed to support and improve commissioning of sexual and reproductive health services.



Online learning

Read more

Treatment pathways

Read more

Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Bayer plc Tel: 01182063500, Fax: 01182063703, Email: pvuk@bayer.com.

If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: qualitycomplaints@bayer.com For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.

  • PP-PF-WHC-GB-0469 July 2020

Copyright © 2019,
Bayer plc

This website is intended for UK healthcare professionals only. Women’s Health Matters is organised and funded by Bayer and contains promotional content.

Prescribing Information (PI) can be found via the links below:
Mirena® (52 mg intrauterine delivery system Levonorgestrel)
Kyleena® (19.5 mg intrauterine delivery system Levonorgestrel)
Jaydess® (13.5 mg intrauterine delivery system Levonorgestrel)
Qlaira® (estradiol valerate/dienogest)
Microgynon® (levonorgestrel/ethinylestradiol)

Page last modified Mon, 08/24/2020 - 03:00

Bayer logo